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In the peripheral nervous system disorders plasticity is related to changes on the axon and Schwann cell biology, and the synaptic
formations and connections, which could be also a focus for therapeutic research. Charcot-Marie-Tooth disease (CMT) represents
a large group of inherited peripheral neuropathies that involvemainly bothmotor and sensory nerves and inducemuscular atrophy
and weakness. Genetic analysis has identified several pathways and molecular mechanisms involving myelin structure and proper
nerve myelination, transcriptional regulation, protein turnover, vesicle traﬃcking, axonal transport and mitochondrial dynamics.
These pathogenic mechanisms aﬀect the continuous signaling and dialogue between the Schwann cell and the axon, having as final
result the loss of myelin and nerve maintenance; however, some late onset axonal CMT neuropathies are a consequence of Schwann
cell specific changes not aﬀecting myelin. Comprehension of molecular pathways involved in Schwann cell-axonal interactions is
likely not only to increase the understanding of nerve biology but also to identify the molecular targets and cell pathways to design
novel therapeutic approaches for inherited neuropathies but also for most common peripheral neuropathies. These approaches
should improve the plasticity of the synaptic connections at the neuromuscular junction and regenerate cell viability based on
improving myelin and axon interaction.
1. Introduction
Charcot-Marie-Tooth disease (CMT) is a clinical and genetic
heterogeneous group of inherited motor and sensory periph-
eral neuropathies (HMSN) that aﬀect 17–40 per 100,000
inhabitants [1, 2]. Mendelian segregation in families may
follow either autosomal dominant, autosomal recessive, or
X-linked patterns. Autosomal recessive forms are described
more frequently in specific populations and geographical
areas such as the Mediterranean basin. Molecular genetic
studies and positional cloning, and more recently exome
sequencing approaches, have unraveled a wide number
of genes involved in the etiology of CMT disease [3–
5]. Molecular genetic studies have been very success-
ful for defining the gene nosology and classification of
inherited peripheral neuropathies; more than 40 genes
have so far been identified to be associated with CMT
and related neuropathies, including rare clinical vari-
ants (http://www.molgen.ua.ac.be/CMTmutations/). As an
immediate consequence, genetic testing has become an
important tool in clinical practice of CMT, and patients and
families have been beneficiated of a more specific genetic
counseling. CMT is caused by mutations in genes that
encode proteins with diﬀerent locations, including compact
and noncompact myelin, Schwann cells, and axons, and
that are involved in very diﬀerent functions, which include
compaction and maintenance of myelin, transport through
myelin, transcription regulation associated withmyelination,
cell signaling, cytoskeleton formation, axonal transport,
mitochondrial dynamics and metabolism, vesicle and endo-
somal traﬃcking, and chaperones. Whatever the metabolic
or structural defect that primarily aﬀects the myelin or the
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axon, the final common pathway in peripheral neuropathies
is represented by an axonal degenerative process that, in
most cases, mainly involves the largest and longest fibers
[6–8]. Signals from axons determine whether or not a
Schwann cell will alter its phenotype and make myelin.
Alternatively, Schwann cell abnormalities may induce axonal
degeneration with or without demyelination. Progress has
been made toward understanding how particular mutations
cause disease, but pathogenic mechanisms remain largely
unknown.
The PNS is a complex network of myelinated and non-
myelinated nerves of varying diameters. A myelinated nerve
fiber consists of a single continuous neuronal process, the
axon, surrounded along the outside by serially arranged
Schwann cells, which enwrap the associated axon with their
cell membrane in a multilayered specialized structure, the
myelin sheath. During development, the acquisition of a
myelinating phenotype by the Schwann cell appears to
be in response to as yet not understood cues from the
axons [9]. When the Schwann cell establishes a one-to-one
association with an axon at the promyelinating stage of its
development, the program of myelination is started and
becomes a myelinating Schwann cell. In contrast, Schwann
cells that do not establish this relationship with an axon
do not activate the program of myelin gene expression and
become nonmyelinating Schwann cells [10]. Interestingly,
this decision process is directed by the axons, as maintenance
of myelin depends on axon and axon integrity. Other
example of the influence of the axons on Schwann cells
is the establishment of an electrically insulate node of
Ranvier. Numerous molecules mediate specific aspects of
the interactions between peripheral axons and Schwann
cells [11] including MAG, p75, IGF1, integrins, and TGF-
β. Neuregulin 1 (Nrg1) and its receptors, the ErbB recep-
tors tyrosine kinases, have emerged as key regulators of
axon-Schwann cell interactions at every stage. Spinal cord
motoneurons, dorsal root ganglia (DRG) sensory neurons,
and autonomic neurons express Nrg1 [12], and Schwann cell
express both ErbB2 and ErbB3 receptors [13]. In addition to
its previously known roles in proliferation and myelination,
Nrg1 type III controls Schwann cell migration. Talbot’s
group have recently demonstrated that Nrg1 type III is
an essential signal that controls Schwann cell migration to
ensure that they are present in the correct numbers and
positions in developing nerves [14]. Inherited demyelinating
neuropathies provide examples of how the axons are also
dependent on Schwann cells. The molecular studies on
the progressive axonal degeneration seen in demyelinating
CMT rodent models have demonstrated that they are likely
to be the result of abnormalities in Schwann cell-axonal
interactions [15–17].
2. CMT: Inheritance and Phenotypes of
Motor and Sensory Neuropathies
CMT disease refers to peripheral neuropathies that aﬀect
both motor and sensory nerves. They are classically sub-
divided into “primary demyelinating” forms (CMT disease
type 1 or CMT1), which are defined by a characteristic
reduction of nerve conduction velocity (NCV) and segmen-
tal demyelination and remyelination, and “primary axonal”
forms (CMT2) that show preservation or mild reduction of
NCVs and loss of axons, namely, those of large diameter
(≥8 μm). As information about CMT2 is increasing, it has
become evident that the distinction between CMT1 and
CMT2 is less clear-cut than what was originally believed
[18]. Diagnosis of CMT2 can be diﬃcult; however, as many
authors have noted, this type of CMT appears to have
greater variability in its clinical presentation than CMT1. The
CMT clinical phenotype is the consequence of a progressive
axonal loss and degeneration aﬀecting preferentially the
longest axons, whatever the underlying primary pathogenic
mechanism, either a myelinopathy and/or axonopathy [6, 7,
19]. CMT is predominantly a large-fibre neuropathy, but as
sural nerve biopsies sometimes show, small fibres may be
involved as well. In spite of the surprising variability of genes
involved in the pathogenesis of CMT, common molecular
pathways have been identified within Schwann cells and
axons that cause these genetic neuropathies [5]. A review
of some of most frequent forms is useful to define relevant
clues to the pathogenesis of CMT and to sum up therapeutic
interventions oriented to modulate the plasticity of these
neuropathies (Figure 1).
2.1. Autosomal Dominant Demyelinating Neuropathies:
CMT1. Approximately 60% of CMT patients show a
predominantly demyelinating peripheral neuropathy and
are classified as CMT1. The main subtype is CMT1A
[20, 21], accounting for 40–50% of all CMT cases, which is
associated with an autosomal dominant 1.4 Mb duplication
on chromosome 17p11.2 that includes the peripheral
myelin protein 22 gene (PMP22) [22, 23], a dosage-sensitive
gene, expressed predominantly in the compact myelin of
Schwann cells of the PNS. Less commonly, point mutations
in PMP22 have been also associated to CMT1. The mirror
mutation, that is, the 1.4 Mb deletion [24, 25], and more
rarely nonsense or frameshift PMP22 mutations [26, 27]
cause the myelinopathy called hereditary neuropathy
with liability to pressure palsies (HNPPs) [28, 29]. Thus,
duplicated or deleted of PMP22 gives rise to demyelinating
neuropathies and secondary axonal loss or abnormalities
by a mechanism of gene dosage. When overexpressed in
cultured cells or in transgenic mice overexpressing the
human gene, PMP22 reaches late endosomes and forms
protein aggregates that are ubiquitinated [30]. Removal
of preexisting aggresomes formed by endogenous PMP22
is aided by autophagy [31]. A second cellular mechanism
that can influence protein aggregation is the heat shock
response. In proteasome-inhibited cells, overexpressed
wild-type and mutant PMP22, as well as the spontaneous
aggregates in neuropathic mouse nerves, recruits heat shock
proteins [31]. The formation of aggresomes is a protective
response of the cell that concentrates misfolded proteins in
a central location to activate an autophagic response [32].
Fortun et al. propose a protective role for chaperones in
preventing the accumulation of misfolded proteins. Elevated
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Figure 1: Peripheral nerve structure and cell localization of some CMT proteins at either the Schwann cell and myelin or the neuronal
axon. (a) PMP22 and P0 are structural proteins located at the compact myelin and Cx32 at the noncompact myelin in the paranode (and
also at the Schmidt-Lanterman incisures). Some other demyelinating CMT-associated molecules are SHT3TC2 at the plasmatic membrane
and related to early endosomes and endosome recycling, the transcription factor ERG2 working in early promyelination programme, and
NDRG1 that is ubiquitously expressed and has been proposed to play a role in growth arrest and cell diﬀerentiation, possibly as a signaling
protein shuttling between the cytoplasm and the nucleus. Proteins mainly related to axonal CMT are associated with neurofilaments (NEFL),
late endosomes (RAB7), mitochondria, endoplasmic reticulum and microtubules (MFN2 and GDAP1), or intermediate filaments (HSP22
and HSP27). (b) A ray sign indicates the main location where drugs or advanced therapies are acting. Stem cell therapy is represented
as an open shadow grasping the neuron soma and axon and the Schwann cell. Trophic factors may be delivered as a drug but also by
means of gene vectors or as a part of the local function of therapeutic stem cells. This figure was produced using Servier Medical Art
(http://www.servier.com/servier-medical-art/powerpoint-image-bank).
PMP22 expression might perturb Schwann cell function by
interfering with the intracellular sorting of PMP22 and other
proteins, leading to overloading of the protein degradation
machinery. Although demyelination is the pathological
and physiological hallmark of CMT1A, the clinical signs
and symptoms of this disease, progressive weakness, and
sensory loss are produced by axonal degeneration [6]. The
characteristic features of the PMP22 mutant Trembler and
Trembler-J mice [33], particularly the minimal or abnormal
myelination and reduced axonal diameter, have made
them very attractive models to define the mechanisms by
which defective peripheral myelination can modify axonal
properties.
CMT1B is caused by mutations in the major myelin
protein zero gene (MPZ), which comprises approximately
50% of myelin protein, and is necessary for both normal
myelin structure and function [34, 35]. To date there are
more than 150 diﬀerent mutations in MPZ known to cause
CMT1B in patients, which include missense, nonsense,
small insertion/deletion, and splice site mutations. Based
on clinical studies, Shy and coworkers’ [36] patients fall
into two distinct phenotype groups: one causing delayed
motor development and marked slow nerve conduction and
a second one usually associated with late-onset neuropathy,
which allows developmental myelination, but eventually
leads to axonal degeneration with minimal evidence of
demyelination. It is diﬃcult to make genotype-phenotype
correlations because mutations in MPZ impair the adhesive
function of myelin protein zero (P0), its subcellular traf-
ficking, or both. Either abnormal gain-of-function eﬀects
(toxicity of misfolded protein) or reduced amounts of P0
(haploinsuﬃciency) could, therefore, underlie the clinical
phenotype [37]. Pennuto and collaborators demonstrated
that the unfolded protein response (UPR) activated by
overload of misfolded proteins in the ER was responsible
for demyelination in a CMT1B mouse model [38]. A recent
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work has identified that an increased gene dosage of MPZ
is directly involved in the pathogenesis of human peripheral
nerves [39].
2.2. Autosomal Dominant Axonal Neuropathies: CMT2.
CMT2 has a highly heterogeneous genotype. Mutations in
the mitofusin 2 gene (MFN2) cause CMT2A and account
for about 20% of CMT2 cases. Other less frequently mutated
genes areMPZ (CMT2J), which also causes CMT1B, and the
neurofilament light chain gene (NEFL) [40, 41].
CMT2A MFN2 participates in the fusion pathway of the
mitochondrial dynamics [42, 43] and is also involved in the
relationship of mitochondria with endoplasmic reticulum
(ER); furthermore, depletion of MFN2 causes a disruption
of mitochondrial dynamics and abnormalities in Ca2+
homeostasis [44]. Mechanisms that have been proposed
to explain the pathophysiology of CMT2A associated with
MFN2 dysfunctions include a defect inmitochondrial fusion,
leading to a loss of mtDNA, and impairment in oxidative
phosphorylation and cell bioenergetics [45]. Current models
propose that a mitochondrial transport defect could be
the cause of CMT2A. Zhao et al. were the first to link
axonal cargo transport dysfunction to CMT2A [46]. Based
on several studies [47, 48], it is tempting to speculate
that MFN2 could be part of a motor complex involved
in anterograde movement of mitochondria. So far, two
transgenic mouse models expressing pathogenic mutations
have been generating, M f n2T105M [49] and M f n2R94Q [50].
Loss of MFN2 profoundly and selectively disrupts axonal
mitochondrial transport [51], which indicates its integral
role in the regulation of mitochondrial transport, and the
important implications for understanding the pathophysiol-
ogy of CMT2A.
To date, up to 18 neurofilament light (NEFL) mutations
have been associated with axonal CMT2E [52, 53]. A con-
ditional mouse model, carrying the P22S mutation, mimics
many aspects of the human CMT2E disease, including motor
disability, abnormal muscle morphology, and denervation
events [54]. These results highlight the importance of
the integrity of the neurofilament network for neuronal
function and suggest that the disease symptoms caused by
the NEFLP22S mutation might result from axonal transport
defects rather than deleterious eﬀects of large neurofilament
aggregates.
2.3. X-Linked CMT. With a frequency of about 10%,
CMTX1 [55] is the second most common inherited neu-
ropathy. CMTX1 is genetically defined by mutations in
the gene GJB1, which encodes the gap junction protein
connexin-32 (Cx32) on the Xq13 chromosome [56]. Cx32
is localized in the noncompacted myelin sheath of large
diameter fibers, forming the functional channels that allow
for the rapid transport of ions and small nutrients between
coupled cells [37]. Although Cx32 expression is not limited
to the peripheral nervous system (it is also expressed by white
matter oligodendrocytes), Cx32 mutations are associated
only with CMT [57]. So far, more than 270 mutations that
alter the structure of Cx32 have been reported, and most of
these probably cause a partial or complete loss of function.
Cx32-deficient mice have prominent adaxonal changes at
the ultrastructural level, and a similar pathomechanism is
observed in humans [58].
2.4. Autosomal Recessive CMT: Demyelinating CMT4 and
Axonal AR-CMT2 Variants. In 2002, Baxter et al. [59]
and Cuesta et al. [60] demonstrated that mutations in
the ganglioside-induced diﬀerentiation-associated protein-1
(GDAP1) gene cause autosomal recessive CMT neuropathy.
This finding was fascinating, as the two reports diﬀered
markedly with respect to the phenotypes of their families.
Cuesta et al. described families who had an axonal phe-
notype (AR-CMT2K), whereas Baxter’s families showed a
demyelinating phenotype (CMT4A). Both slow and normal
NCVs have been reported in patients, and many of the cases
show a severe phenotype and have their onset in childhood.
However, mild forms segregating as an autosomal dominant
phenotype have also been reported [61]. Mutations have
been described in every exon and include missense, non-
sense, splicing site, short deletions, and insertion mutations.
GDAP1 belongs to a glutathione S-transferase enzyme
subfamily [62] that is mainly expressed in neurons [63, 64]
but also in Schwann cells [65]. GDAP1 is a mitochondrial
protein [63] located in the mitochondrial outer membrane
(MOM) acting as a regulator of mitochondrial dynamics [65,
66]. The eﬀect of GDAP1 mutations in mitodynamics seems
to depend on the inheritance pattern [67]. Overexpression
of GDAP1 in COS7 or HeLa cells causes mitochondrial
fragmentation or fission and a substantial accumulation of
mitochondria around the nucleus. Rescue experiments in
Saccharomyces cerevisiae defective mutans for fission and
fusion genes have shown that GDAP1 rescues the phenotype
of the fission-associated gene Fis1. In particular, the recovery
of G2/M delay suggests that both Fis1p and GDAP1 may
aﬀect the interaction of mitochondria with microtubules
[68], an aspect that may relate GDAP1 to mitochondrial
transport or movement in axons.
CMT4C neuropathy, which is caused by mutations in the
SH3TC2 gene, is the most common cause of the autosomal
recessive form of demyelinating CMT. SH3TC2 is specifically
expressed in Schwann cells and is necessary for proper
myelination of peripheral axons. Analysis of the murine
model of CMT4C revealed that the capacity of SH3TC2-
deficient Schwann cells to properly myelinate underlying
axons is aﬀected at the early stages of myelination, which is
in line with the early onset of the neuropathy reported in
CMT4C patients [69–71]. However, its exact role in myelin
biology remains to be determined. Recent data demonstrated
that SH3TC2 localizes at the plasma membrane and in
endocytic vesicles [72–74] and that it interacts with the small
GTPase Rab11, which is known to regulate the recycling of
internalized membranes and receptors back to the plasma
membrane. Further protein binding studies and transferrin
receptor traﬃcking assays revealed that SH3TC2 together
with Rab11 indeed aﬀect the dynamics of endocytic recycling
[75].
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3. Cellular andMolecular Bases of
Nerve Regeneration and Plasticity in
CMTNeuropathies
The discovery of many genes involved in CMT disease has
provided a unique opportunity to understand the critical
molecular pathways involved in peripheral axon stability
and length-dependent peripheral nerve disease [17, 18].
An important concept in peripheral neuropathy is that
many types are characteristically length dependent; that is,
the longest axons in the body are aﬀected first and most
profoundly. The length-dependent distribution supports the
concept that the major site of pathology is in the axon
itself, rather than the cell body. Furthermore, it suggests
that shorter axons are either less susceptible or better able
to compensate for certain insults that are longer axons,
leading to the degeneration of the distal regions of the longest
axons first [76]. Peripheral neuropathies presenting a distal
nonterminal axonopathy represent the most common nerve
diseases. Their long-term outcome depends on the balance of
two processes: the degree or rate of axonal degeneration and
the ability of the nascent axon tips to regenerate eﬃciently.
One strategy to alter these processes would be to improve
the eﬃciency of regeneration by using trophic factors
such as neurotrophins [77], moving them from bench-
to bedside. Prolonged denervation could lead to decreased
regeneration capacity because of reduction in the expression
of regeneration-associated Schwann cell molecules, such as
neurotrophic factors and receptors. Therefore, Schwann cells
might remain in a growth-supportive mode for prolonged
periods or they have to be transformed into a competent
premyelinating state to initiate and complete myelination.
The functional significance of regeneration is to allow
reinnervation of target organs and restitution of their
corresponding functions. The materials for axonal growth
are mainly provided by the cell body via axonal transport
[78, 79], but more recently the contribution of local axonal
synthesis and degradation of proteins has been identified
[80, 81]. Increased energy demands on the neuron to
propagate action potentials, and decreased trophic factor
support from denervated Schwann cells or muscle are other
potential mechanisms that may also contribute to axonal
degeneration in demyelinating neuropathies (reviewed in
[16]). An unanswered question with respect to all CMT1
forms is why mutant Schwann cells fail to support axonal
function and survival [37]. An important direction is the
development of therapeutic strategies that enhance axonal
regeneration and promote selective target reinnervation; in
addition, modulation of the central nervous system reorga-
nization to improve functional recovery but also diminishing
undesirable consequences has been proposed as well [82].
4. CMT Pharmacological and
Biological Therapies
CMT disease course and severity vary according to CMT
type, causative gene, and mutation change, but considerable
phenotypic variability may occur also within the same CMT
type. Understanding the molecular pathogenesis of inherited
neuropathies is essential for the development of rational
therapies (Figure 1). While much remains to be learned,
it is clear that most are caused by the expression of a
mutant allele(s) inmyelinating Schwann cells or neurons. For
recessive neuropathies, in principle it is possible to “replace”
the defective gene by introducing a normal version. For
dominant neuropathies, the situation is even more complex,
as these are likely to be caused by a toxic gain of function
that is not necessarily related to the normal function of
the gene product. Nevertheless, for dominant demyelinating
neuropathies caused by altered gene dosage, reestablishing
the normal level of gene expression might be of benefit. The
pathogenic mechanism in CMT1A duplication is attributed
to an excess gene copy number of PMP22, leading to protein
overexpression [28], and factors that modify the expression
levels of PMP22 might potentially be eﬀective for treatment.
A proof of concept that demyelination can be reversed by
normalizing expression of PMP22 was provided through
a transgenic mouse model [83]. Research is focused on
developing new treatment strategies to target the regulation
of PMP22 gene dosage. Two compounds that have been
shown to alter PMP22 mRNA levels in rodents are ascorbic
acid and progesterone and progesterone antagonists.
Ascorbic acid reduced the severity of neuropathy in
transgenic mice overexpressing PMP22, an animal model
of human CMT1A, compared with untreated mice [84].
Ascorbic acid promotes myelination in vitro and decreases
PMP22 mRNA levels through a cAMP-mediated pathway
[84, 85]. Evidence of eﬃcacy of ascorbic acid in the animal
model prompted initiation of randomized controlled trials
to test the eﬃcacy of ascorbic acid in patients with CMT1A.
Results from a phase 3, multicentre, placebo-controlled,
double-blind randomized trial to assess the eﬃcacy and
tolerability of chronic ascorbic acid treatment in patients
with CMT1A in Italy and the UK have been just published
[86]. Unfortunately, ascorbic acid supplementation had no
significant eﬀect on neuropathy compared to placebo after
2 years followup, suggesting that no evidence is available to
support treatment with ascorbic acid in adults with CMT1A.
It is known that progesterone and derivates are able
to increase MPZ and PMP22 gene expression in vitro
[87]. In order to test if progesterone can modulate the
progressive neuropathy caused by moderate overexpression
of PMP22, Sereda and collaborators [88] administrated daily
subcutaneous injections of progesterone and the proges-
terone antagonist, onapristone, to a transgenic rat model
of CMT1A during 7 weeks and showed that onapristone
reduced PMP22 mRNA by 15%, resulting in clinical and
neuropathological improvement. A long-term study reaf-
firmed these results and shed light to the axonal degeneration
process seen in CMT1A patients, by reducing progressive
muscle atrophy and preventing axonal loss without altering
myelin sheath thickness [89]. Unfortunately, onapristone
and currently available progesterone antagonists are too
toxic to be safely administered to CMT1A patients, so
further research is ongoing to develop suitable compounds
for future clinical trials. To accomplish this goal, the
Charcot-Marie-Tooth Association (CMTA) has established
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the Strategy to Accelerate Research (STAR) to specifi-
cally fund CMT-related research (http://www.cmtausa.org/).
High-throughput screens are trying to identify compounds
that are already FDA approved, so it could accelerate the drug
development process and start phase III clinical trials in 3–5
years.
Another interesting and promising molecule is cur-
cumin, which plays a role stimulating the translocation
of misfolded proteins from the endoplasmic reticulum to
the plasma membrane, thereby reducing cytotoxicity of
the mutant proteins. This mechanism might be helpful
for selected CMT1A and CMT1B forms, in which various
PMP22 andMPZ mutations are known to cause intracellular
accumulation of mutant proteins. Oral curcumin mitigates
the clinical and neuropathologic phenotype of Trembler-J
mouse model of CMT1A, inhibiting Schwann cell apoptosis
and increasing axonal caliber and myelin thickness. Further-
more, this positive clinical response to curcumin occurs in
a dose-dependent manner and is reversed after withdrawal
of treatment without side eﬀects. Recent cell-based studies
showed that mutant P0 could accumulate in the ER and
induce apoptosis. This aggregation-induced apoptosis was
abrogated by pretreatment with curcumin [90]. These
findings suggest a potential therapeutic role of curcumin in
selected forms of inherited peripheral neuropathies. There
is also evidence that MPZ mutations with ER-retention
of the mutated protein cause UPR activation rather than
apoptosis [38] so this mechanism could also be relevant as
a therapeutic target.
Regarding axonal CMT, in a transgenic mouse model
for mutant HSBP1-induced CMT2 and distal HMN type 2B
[91], mutant HSBP1, also known as HSP27, leads to severe
axonal transport defects induced by a decrease in acetylated
tubulin abundance in peripheral nerves. The phenotype
was partially restored and the axonal transport defects were
rescued when mice were treated with HDAC6 inhibitors.
Histone deacetylase 6 (HDAC6) is the major enzyme with
α-tubulin deacetylating activity. For this study the authors
used a nonspecific inhibitor, trichostatin A (TSA), and
two highly selective inhibitors: tubacin and tubastatin A,
which resulted to be more eﬀective compared to TSA when
axonal transport and CMT phenotype were assessed. As
some HDAC6 inhibitors have entered into clinical trials for
cancer treatment and other neurological disorders such as
Friedreich’s ataxia [92], it is rationale to think that the same
drug approach could be tested in CMT patients.
Schwann cell pathology damages the delicate myelin-
axon interaction and can lead to axonal degeneration [6], but
pronounced axonal pathology has also been observed even in
genetic models in which axons are associated with normal
appearing myelin sheaths. Thus, a therapeutic approach
focusing on preventing this intimate connection could be
providing trophic factor support to degenerating axons,
which may be useful for a number of CMT neuropathies,
either primary myelinopathies or primary axonopathies. The
main conceptual problem with this approach is the diversity
of trophic factors and PNS neurons, especially because
diﬀerent kinds of neurons respond to diﬀerent trophic
factors [16]. Only neurons with the proper receptors typi-
cally respond to a given growth factor. Receptor-mediated,
retrograde axonal transport delivers the trophic factor to
neuronal cell bodies, where they act. Axonal elongation
requires an adequate substrate of trophins and tropic factors,
provided by reactive Schwann cells and the extracellular
matrix within the degenerated nerve [93]. Another poten-
tially approach involves the manipulation of Schwann cell-
axonal signal transduction pathways. Neuregulin-1 enhances
axonal regeneration [94] by acting on Schwann cells as
PNS neurons do not express neuregulin receptors. Axons
express neuregulin-1 type III (Nrg1-III) on their surface,
which binds to ErbB receptors on Schwann cells as part
of a process that initiates myelination. Therefore, Nrg1-III
acts as a juxtacrine signal. Nrg1-III binds to ErbB3 and
promotes ErbB2 phosphorylation of tyrosine residues in the
cytoplasmic domain of both ErbB2 and ErbB3 receptors [95].
Activation of the ErbB receptors leads to signaling through
multiple signaling cascades including PI3K/Akt, Erk1/2,
JNK, and FAK [96]. Three families of trophic factors are
particularly important for PNS neurons: the neurotrophin
family, the glial-derived neurotrophic factor (GDNF), and
the ciliary neurotrophic factor (CNTF) family of cytokines.
Sahenk and collaborators studied the ability of mutant
Schwann cells to respond to exogenous neurotrophin-3 (NT-
3) in two CMT1A animal models [97]. NT-3-treated animals
presented improved nerve regeneration and the associated
myelination process. Furthermore, at the early stages of
regeneration-associated myelination, NT-3 stabilizes the
axonal cytoskeleton locally by inducing neurofilament phos-
phorylation when axon sprouts become enwrapped by
Schwann cells [77]. In contrast, BDNF, which belongs to
the neurotrophin family but is not part of the Schwann cell
survival loop [98], showed no eﬀect upon axonal growth or
cytoskeletal neurofilament pathology. Unfortunately, despite
the promising results in animal studies, no studies have been
successful in humans, probably due to a poor delivery and
short half-lives of the trophic and growth factors. Targeting
the correct combination of trophic factors to neurons or
Schwann cells at the optimal time may be necessary to
achieve meaningful results. A combination of trophic factors
or engineered “pan-neurotrophic factors” [99] might be
more beneficial than a single factor.
The short half-life of most neurotrophic factors would
require either multiple administrations or a continuous
infusion of the therapeutic molecules in order to achieve
an adequate and eﬀective local concentration. Knowing the
molecular basis of inherited diseases prompts immediate
consideration of gene therapy. Gene therapy can be defined
as a strategy to transfer biologically relevant genetic material
(usuallymutant genes or genes delivering trophic and growth
factors) into aﬀected cells in the body to treat disease. For
instance, delivering neurotrophic factors to the healing nerve
ends, favoring survival and regeneration of both sensory
and motor axons, could, ultimately, allow the recovery of
nervous functions [100]. Viral vectors and plasmid DNA
have been widely used for treating human disease models
and patients. Expression of the gene might be modulated by
the introduction of regulatory elements for the controlled or
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tissue-specific expression of the desired molecule. Until now,
three major classes of viral vectors, based on adenovirus,
adeno-associated virus (AAV), and herpes simplex virus
(HSV), have been exploited to target the PNS. Although not
originally neurotropic, adenoviral and AAV vectors are able
to transduce spinal sensory and motor neurons after either
intramuscular or intraneural injections. When injected at
the site of a nerve injury, these vectors are retrogradely
transported to motor neuron cell bodies and can thus be
exploited to deliver therapeutic genes along the route of the
nerve. However, the strong absorption of both adenoviral
and AAV vectors to skeletal muscle fibers might represent a
limitation for eﬃcient neuronal transduction and retrograde
transport [101]. A recent study in mice has characterized
the tropism and transduction eﬃciency of diﬀerent AAV
pseudotypes after sciatic nerve injection. Among the pseu-
dotypes tested, AAV2/1 transduced both Schwann cells and
neurons, AAV2/2 infected only sensory neurons, and AAV2/8
preferentially transduced Schwann cells, proving the utility
of AAVs as gene therapy vectors [102]. A few approaches
have used plasmids as vehicles to deliver therapeutic genes
to peripheral nerves. In these cases, the skeletal muscle has
been the preferred site for delivery and expression of the
transgene. For instance, intramuscular delivery of a plasmid
encoding for vascular endothelial growth factor (VEGF)
showed a protective role against myelin wasting and axonal
loss [103]. Viral vectors have been modified so that they
are unable to cause disease. Unfortunately, they have caused
immunologic reactions, which currently limit their use.
In contrast, plasmid DNA is nonimmunogenic, but it is
characterized by poor delivery eﬃciency, and proteins made
from it have only been produced in target organs for a
short time. Progress in this area demands more sophisticated
delivery systems and more knowledge of the molecular
pathogenesis of neuropathies.
Schwann cells, and their basal lamina, represent the
key component of nerve regeneration, as they serve as
scaﬀolds for the regenerating axons, which grow through
the empty basal lamina tubes. Schwann cells, however,
have limited clinical applications since the culture of an
adequate quantity of cells to achieve optimal conditions
for transplantation in nerve conduits is time consuming
and requires particular care for in vitro expansion and
a constant input of growth factors. Moreover, Schwann
cells are not easily accessible without nerve biopsy and
bear the need to sacrifice an autologous nerve, with the
related complications. Due to all these diﬃculties, the field
of stem cell therapy for peripheral neuropathies has been
explored. Adult stem cells show ability to diﬀerentiate into
neuroprogenitor-type cells [104, 105]. Stem cells could
be diﬀerentiating into neurons, which will generate new
axons to contact their targets or Schwann cells enwrapping
demyelinating axons and secreting trophic factors. Bone-
marrow-derived mesenchymal stem cells (MSCs) can be
induced to diﬀerentiate into Schwann cells [106], improving
myelin formation and nerve regeneration in vivo after their
transplantation into diﬀerent models of peripheral nerve
injury [107, 108]. Adipose tissue has been also indicated as
a novel and promising source of multipotent cells (adipose-
derived stem cells, ASCs), which can be diﬀerentiated into a
neuronal phenotype [109, 110], and in terms of clinical use,
theymay be harvested by conventional liposuction procedure
under local anaesthesia. The frequency of stem cells in
adipose tissue is 100- to 1000-fold higher than that in bone
marrow, which is a considerable advantage as it reduces the
period of expansion of the stem cells prior to diﬀerentiation.
Terenghi’s group showed how ASCs could be diﬀerentiated
towards a Schwann cell-like phenotype, expressing markers
like S-100, glial fibrillary acidic protein (GFAP) and P75
neurotrophin receptor and enhancing neurite outgrowth in
an in vitro co-culture model [111]. More recently, expression
of myelin proteins P0 and PMP22 after diﬀerentiation of
both ASC and MSC [112] and the neurotrophic potential
shown in vitro from diﬀerentiated adipose-derived stem cells
(dASCs) with a brief term in vivo study have been described
[113].
5. Conclusions
Charcot-Marie-Tooth disease is a generalized disorder of
motor and sensory peripheral nerves. Three major points
deserve attention: (1) disease pathophysiology of both
myelinopathies and axonopathies forms are the consequence
of altered Schwann cell-axon communication; abnormal
intercellular contact and signaling induce neurodegeneration
and axonal loss, which ultimate produce muscular atrophy
and weakness, (2) the primary cause is the genetic mutation
in any of the more than 40 genes causing CMT or related
neuropathies, and (3) a major therapeutic target is the
regeneration of cell viability based on improving myelin and
axon interaction. Therapies promoting plasticity changes in
axons and Schwann cells require not only new therapeutic
drug, gene, or cell approaches but also proper delivery
systems targeted to the pathological cellular structures.
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